Sudip Pharma lifts quarterly revenue to 196.6991 crore rupees in the second quarter
Key Facts
Sudip Pharma reported consolidated revenue from operations of 196.6991 crore rupees in the second quarter of fiscal 2027, ended 30 September 2026, compared with 162.6662 crore rupees a year earlier and 158.2705 crore rupees in the first quarter. The company’s board approved the unaudited standalone and consolidated results for the quarter and half year at its meeting on 28 October 2026. Consolidated total income was 202.6834 crore rupees, against 172.8317 crore rupees in the second quarter of the previous fiscal year. Profit before tax was 71.0325 crore rupees, up from 59.5337 crore rupees a year earlier. Profit for the period was 51.8111 crore rupees, compared with 46.7782 crore rupees. The results cover the quarter ended in September, not the second quarter of calendar 2027.
The quarterly comparison shows that revenue growth was not matched by a similar increase in net profit. Revenue from operations rose from its year-earlier level, while profit for the period increased from 46.7782 crore rupees to 51.8111 crore rupees. Basic and diluted earnings per share were 4.59 rupees, compared with 4.20 rupees in the corresponding quarter of fiscal 2026. This places profitability and per-share measures alongside revenue growth, without the company attributing the changes to a specific operational cause in its disclosure. The disclosure did not describe revenue or operating profit as record levels, nor did it link the results to business expansion. These consolidated results are unaudited, while the auditor’s report was limited to a review of the quarter ended 30 September 2026.
By segment, the pharmaceuticals and food and nutrition segment recorded quarterly revenue of 142.4996 crore rupees and a segment result after depreciation of 55.1234 crore rupees. The specialty ingredients segment generated revenue of 54.1995 crore rupees, with a segment result after depreciation of 12.7379 crore rupees. The disclosure thus presents the two businesses’ results within total consolidated revenue for the period. The figures show differences in revenue and segment result between the two businesses, with both recording positive revenue and results. The disclosure provides no explanation of the factors that drove each segment’s performance.
For the half year ended 30 September 2026, consolidated revenue from operations was 354.9696 crore rupees, compared with 287.5837 crore rupees in the same period of the previous fiscal year. This places the second-quarter figures within a six-month period that also recorded year-on-year revenue growth. The investor relations page lists the second-quarter fiscal 2027 results and investor presentation among its quarterly materials. The board approved the current results on 28 October; they cover the quarter and half year through the end of September.